Oxidative stress and cancer: The role of redox regulation

Biotherapy

Volumn 11, Issue 2-3, 1998, Pages 147-154

  Toyokuni, Shinya ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT ACTIVITY; CARCINOGENESIS; CHEMICAL CARCINOGENESIS; CONFERENCE PAPER; DNA DAMAGE; IRON OVERLOAD; LIPID PEROXIDATION; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; REPERFUSION INJURY; ULTRAVIOLET RADIATION;

ANIMALS; BIOLOGICAL MARKERS; CELL TRANSFORMATION, NEOPLASTIC; HOMEOSTASIS; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; OXIDATION-REDUCTION; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

EID: 0031747807     PISSN: 0921299X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007934229968     Document Type: Conference Paper

References (80)

1. Adelman R, Saul RL, Ames BN. Oxidative damage to DNA: relation to species metabolic rate and life span. Proc Natl Acad Sei USA 1988; 85: 2706-08.
2. Fraga CG, Shigenaga MK, Park JW, Degan P and Ames BN. Oxidative damage to DNA during aging: 8-hydroxy-2'deoxyguanosine in rat organ DNA and urine. Proc Natl Acad Sei USA 1990; 87: 4533-7.
3. Halliwell B, Gutteridge JMC. Free radicals in biology and medicine. 2nd ed., Oxford: Clarendon Press, 1989; 33-46.
4. Esterbauer H, Schauur JS, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radie Biol Med 1991; 11: 81-128.
5. Uchida K, Stadtman ER. Modification of histidine residues in proteins by reaction with 4-hydroxynonenal. Proc Natl Acad Sei USA 1992; 89: 4544-8.
6. Uchida K, Szweda LI, Chae H-Z, Stadtman ER. Immunochemical detection of 4-hydroxynonenal protein adducts in oxidized hepatocytes. Proc Natl Acad Sei USA 1993; 90: 8742-6.
7. Toyokuni S, Miyake N, Hiai H, Hagiwara M, Kawakishi S, Osawa T, Uchida K. The monoclonal antibody specific for the 4-hydroxy-2-nonenaI histidine adduct. FEBS Lett 1995; 359: 189-91.
8. Luo XP, Yazdanpanah M, Bhooi N, Lehotay DC. Determination of aldehydes and other lipid peroxidation products in biological samples by gas chromatography-mass spectrometry. Anal Biochem 1995; 228: 294-8.
9. Kasai H, Nishimura S. Hydroxylation of deoxyguanosine at the C-8 position by ascorbic acid and other reducing agents. Nucleic Acids Res 1984; 12: 2137-45.
10. Floyd RA, Watson JJ, Wong PK, Altmiller DH, Rickard RC. Hydroxyl free radical adducts of deoxyguanosine: sensitive detection and mechanisms of formation. Free Radie Res Commun 1986; 1: 163-172.
11. Floyii RA. The role of 8-hydroxyguanine in carcinogenesis. Carcinogenesis 1990; 11: 1447-50.
12. Kuchino Y, Mori F, Kasai H, Inoue H, Iwai S, Miura K, Ohtsuka E, Nishimura S. DNA templates containing 8hyclroxydeoxyguanosine are misread both at the modified base and at adjacent residues. Nature 1987; 327; 77-9.
13. Shibutani S, Takeshita M, Grollman AP. Insertion of specific bases during DNA synthesis past the oxidation-damaged base 8-oxodG. Nature 1991; 349; 431-4.
14. Modrich P. Mechanisms and biological effects of mismatch repair. Ann Rev Genet 1991; 25: 229-53.
15. Dizdaroglu M. Chemical determination of free radicalinduced damage to DNA. Free Radie Biol Med 1991; 10: 225-242.
16. Chaudhary AK, Nokubo M, Reddy GR, Yeola SN, Morrow JD, Blair IA, Marnett LJ. Detection of endogenous malondialdehyde-deoxyguanosine adducts in human liver. Science 1994:265: 1580-2.
17. Toyokuni S. Iron-induced carcinogenesis: the role of redox regulation. Free Radie Biol Med 1996; 20: 553-66.
18. Hayashi T, Ucno Y, Okamoto T. Oxidoreductive regulation of nuclear factor kappa B: involvement of a cellular reducing catalyst thioredoxin. J Biol Chem 1993; 268: 11380-8.
19. Weitzman SA, Gordon LI. Inflammation and cancer: role of phagocyte-generated oxidants in carcinogenesis. Blood 1990; 76: 655-63.
20. Wriggleworth JM, Baum H. The biochemical function of iron. In: Iron in biochemistry and medicine, II, A Jacobs, M Worwood, eds. London: Academic Press, 1980; 29-86.
21. deDuve C. Blue print for a cell: the nature and origin of life. Burlington, NC: Neil Patterson Publishers, 1991; 123-70.
22. Cotran RS, Kumar V, Robbins SL. Robbins Pathologic Basis of Disease. 4th ed., Philadelphia: WB Saunders, 1989; 239305.
23. Niederau C, Fischer R, Sonnenberg A, Stremmel W, Trampisch HJ, Strohmyer G. Survival and causes of death in cirrhotic and in noncirrhotic patients with primär)' hemochromatosis. N Engl J Med 1985; 313: 1256-62.
24. Bradbear RA, Bain C, Siskind V, Schofield FD, Webb S, Azelsen EM, Halliday JW. Bassett ML, Powell LW. Cohort study of internal malignancy in genetic hemochromatosis and other chronic non-alcoholic liver diseases. J Natl Cancer Inst 1985; 75: 81-4.
25. Hsing AW, McLaughlin JK, Olsen JH, Mellemkjar L, Wacholder S, Fraumeni JF Jr. Cancer risk following primary heniochromatosis: a population-based cohort study in Denmark. Im J Cancer 1995; 60: 160-2.
26. Mossman BT, Bignon J, Corn M, Seaton A, Gee JBL. Asbestos: scientific developments and implications for public policy. Science 1990; 247: 294-301.
27. Stevens RG, Jones DY, Micozzi MS, Taylor PR. Body iron stores and the risk of cancer. N Engl J Med 1988; 319: 1047-52.
28. Richmond HG. Induction of sarcoma in the rat by iron-dextran complex. Br Med J 1959; i:947-949.
29. Okada S, Midorikawa O. Induction of rat renal adenocarcinoma by Fe-nitrilolriacetate (Fe-NTA). Jpn Arch Intern Med 1982; 29:485-91.
30. Ebma Y, Okada S, Hamazaki S, Ogino F, Li J-L, Midorikawa C). Nephrotoxicity and renal cell carcinoma after use of iron- and aluminum-nitriotriacetate complexes in rats. J Natl Cancer Inst 1986; 76: 107-13.
31. Li J-L, Okada S. Hamazaki S, Ebina Y, Midorikawa O. Subacute nephrotoxicity and induction of renal cell carcinoma in mice treated with ferric nitrilotriacetate. Cancer Res 1987; 47: 1867-9.
32. Mottola HA. Nitrilotriacetic acid as a chelating agent: applications, toxicology, and bio-environmental impact. Toxicol Environ Chem Rev 1974: 71: 99-161.
33. Anderson RL, Bishop WE, Campbell RL. A review of the environmental and mammalian toxicology of nitrilotriacetic acid. Crit Rev Toxicol 1985; 15: 1-102.
34. Bates GW, Schlabach MR. The reaction of ferric salts with transferrin. J Biol Chem 1973; 248: 3228-32.
35. Okada S, Hamazaki S, Ebina Y, Li J-L, Midorikawa O. Nephrotoxicity and its prevention by vitamin E on ferric nitrilotriacetate-promoted lipid peroxidation. Biochim Biophys Acta 1987; 922: 28-33.
36. Hamazaki S, Okada S, Li J-L, Toyokuni S, Midorikawa O. Oxygen reduction and lipid peroxidation by iron chelates with special reference to ferric nitrilotriacetate. Arch Biochem Biophys 1989; 272: 10-7.
37. Toyokuni S, Okada S, Hamazaki S, Minamiyama Y. Yamada Y, Liang P, Fukunaga Y, Midorikawa O. Combined histochemical and biochemical analysis of sex hormone dependence of ferric nitrilotriacetate-induced renal lipid peroxidation in ddY mice. Cancer Res 1990; 50: 5574-80.
38. Okada S, Minamiyama Y, Hamazaki S, Toyokuni S, Sotomatsu A Glutathione cycle dependency of ferric nitrilotriacetate-induced lipid peroxidation in mouse proximal renal tubules. Arch Biochem Biophys 1993; 301: 138-42.
39. Toyokuni S, Sagripanti J-L. DNA single- and double-strand breaks produced by ferric nitrilotriacetate in relation to renal tubular carcinogenesis. Carcinogenesis 1993; 14: 223-7.
40. Hamazaki S, Okada S, Ebina Y, Li J-L, Midorikawa O. Effect of dietary vitamin E on ferric nitrilotriacetate-induced nephrotoxicity in rats. Toxicol Appl Pharmacol 1988; 92: 500-506.
41. Toyokuni S, Uchida K, Okamoto K, Hattori-Nakakuki Y, Hiai H, Stadtman ER. Formation of 4-hydroxy-2-nonenal-modified proteins in the renal proximal tubules of rats treated with a renal carcinogen, ferric nitrilotriacetate. Proc Natl Acad Sei USA 1994; 91: 2616-20.
42. Okada S, Fukunaga Y, Hamazaki S, Yamada Y, Toyokuni S. Sex differences in the localization and severity of ferric nitrilotriacetate-induced lipid peroxidation in the mouse kidney. Acta Pathol Jpn 1991 ; 41: 221 -6.
43. Toyokuni S, Uchida K, Okamoto K, Hattori-Nakakuki Y, Hiai H, Stadtman ER. Formation of 4-hydroxy-2-nonenal-inodified proteins in the renal proximal tubules of rats tretated with a renal carcinogen, ferric nitrilotriacetate. In: Vlth International Conference on Superoxide and Superoxide Distnutase, Kyoto, 11-15 October 1993, Excerpta Medica International Congress Series 1058. Amsterdam: Elsevier, 1994; 171-172.
44. Uchida K, Fukuda A, Kawakishi S, Hiai H, Toyokuni S. A renal carcinogen ferric nitrilotriacetate mediates a temporary accumulation of aldehyde-modified proteins within cytosolic compartment of rat kidney. Arch Biochem Biophys 1995; 317:405-11.
45. Toyokuni S, Mori T, Dizdaroglu M. DNA base modifications in renal chromatin of Wistar rats treated with a renal carcinogen, ferric nitrilotriacetate. Int J Cancer 1994; 57: 123-8.
46. Toyokuni S, Mori T, Hiai H, Dizdaroglu M. Treatment of Wistar rats with a renal carcinogen, ferric nitrilotriacetate, causes DNA-protein cross-linking between thymine and tyrosine in their renal chromatin. Int J Cancer 1995: 62: 309-13.
47. Nishiyama Y, Suwa H, Okamoto K, Fukumoto M, Hiai H, Toyokuni S. Low incidence of point mutations in H-, K- and N-ras oncogenes and p53 tumor suppressor gene in renal cell carcinoma and peritoneal mesothelioma of Wistar rats induced by ferric nitrilotriacetatc. Jpn J Cancer Res 1995; 86: 1150-8.
48. Shields PC, Harris CC. Molecular epidemiology and the genetics of environmental cancer. J Am Med Assoc 1991; 266:681-7.
49. Higinbotham KG, Rice JM, Diwan BA, Kasprzak KS, Reed CD, Perantoni AO. GOT to GTT transversions in eodon 12 of the K-ras oncogene in rat renal sarcomas induced with nickel subsulfide or nickel subsultide/iron are consistent with oxidative damage to DNA. Cancer Res 1992; 52: 4747-51.
50. McBride TJ, Preston BD, Loeb LA. Mutagenic spectrum resulting from DNA damage by oxygen radicals. Biochemistry 1991; 30: 207-13.
51. Reid TM, Loeb LA. Tandem double CC to TT mutations are produced by reactive oxygen species. Proc Natl Acad Sei USA 1993:90:3904-7.
52. Nakatsuka S, Tanaka H, Namba M . Mutagenic effects of ferric nitrilotriacetate (Fe-NTA) on V79 Chinese hainster cells and its inhibitory effects on cell-cell communication. Carcinogenesis 1990; 11: 257-60.
53. Toyokuni S, Sagripanti J-L, Hitchins VM. Cytotoxic and mutagenic effects of ferric nitrilotriacetate on L5178Y mouse lymphoma cells . Cancer Lett 1995: 88: 157-62.
54. Dabbagh AJ, Mannion T, Lynch SM, Frei B. The effect of iron overload on rat plasma and liver oxidant status in vivo. Biochem J 1994; 300 (pt 3): 799-803.
55. Bonkovsky HL, Healey JF, Lincoln B, Bacon BR, Bishop DF, Elder GH. Hepatic heme synthesis in a new model of experimental hemochromatosis: studies in rats fed finely divided elemental iron. Hepatology 1987; 7: 1195-203.
56. Kawabata T, Ogino T, Awai M. Protective effects of glutathione against lipid peroxidation in chronically iron-loaded mice. Biochim Biophys Acta 1989; 1004: 89-94.
57. Fletcher LM, Roberts FD, Irving MG, Powell LW, Halliday JW. Effects of iron loading on free radical scavenging enzymes and lipid peroxidation in rat liver. Gastroenterology 1989;97: 1011-1018.
58. p, isozyme. Arch Biochem Biophys 1996; 329: 39-46.
59. 1ARC Working Group on the Evaluation of the Carcinogenic Risk of Chemicals to Man Nickel and nickel compounds. In 1ARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Man, Vol.11, Lyon, IARC), 1976; 75-112.
60. Chovil A, Sutherland RB, Halliday M. Respiratory cancer in a cohort of nickel sinter plant workers. Br J Ind Med 1981; 38: 327-33.
61. Oilman JPW. Metal carcinogenesis. II. A study on the carcinogenic activity of cobalt, copper, iron, and nickel compounds. Cancer Res 1962; 22: 158-62.
62. Sunderman FW, Jr, Maenza RM. Comparisons of carcinogenicities of nickel compounds in rats. Res Commun Chein Pathol Pharmacol 1976; 14: 319-30.
63. Sunderman FW, Jr. Recent advances in metal carcinogenesis. Ann Clin Lab Sei 1984; 14: 93-122.
64. Sunderman FW, Jr, Maenza RM, Hopler SM, Mitchell JM, Allpass PR, Damjanov I. Induction of renal cancers in rats by intrarenal injection of nickel subsulfide. J Environ Pathol Toxicol 1979; 2: 1511-27.
65. Mon M, Hallon A, Sawaki M, Tsuzuki N, Sawada N, Oyamada M, Sugawara N, Enomoto A. The LEC rat: a model for human hepatitis, liver cancer, and much more. Am J Pathol 1994; 144: 200-4.
66. Wu J, Forhes JR, Chen HC, Cox DW. The LEG rat has a deletion in the copper transporting ATPase gene homologous to the Wilson disease gene. Nature Genet 1994; 7: 541-5.
67. Li Y, Togashi Y, Sato S, Emoto T, Rang J-H, Takeichi N, Kobayashi H, Kojima Y, Une Y, Uchino J. Abnormal copper accumulation in non-cancerous and cancerous liver tissue of LEG rats developing hereditary hepatitis and spontaneous hepatoma. Jpn J Cancer Res 1991 ; 82: 490-2.
68. Sugawara N, Sugawara C, Katakura M, Takahashi H, Mon M. Copper metabolism in the LEG rat: involvement of induction of metallothionein and deposition of zinc and iron. Experimentia 1991; 47: 1060-3.
69. Toyokuni S, Okada S, Hamazaki S, Fujioka M, U J-L and Midorikawa O. Cirrhosis of the liver induced by cupric nitrilotriacetate in Wistar rats: an experimetnal model of copper toxicosis. AmJ Pathol 1989; 134: 1263-74.
70. Hann H-WL, Stahlhut MW, Menduke H. Iron enhances tumor growth: observation on spontaneous mammary tumors in mice. Cancer 1991; 68: 2407-10.
71. Yoshiji H, Nakane D, Kinugasa T, Matsuzaki M, Denda A, Tsujii T, Konishi Y. Inhibitory effect of dietary iron deficiency on the induction of putative preneoplastic foci in rat liver with diethylnitrosamine promoted by phénobarbital. Br J Cancer 1992; 64: 839-42.
72. Szatrowski TP, Nathan CF. Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res 1991; 51:794-8.
73. Okamoto K, Toyokuni S, Uchida K, Ogawa O, Takenewa J, Kakehi Y, Kinoshita H, Hattori Nakakuki Y, Hiai H, Yoshida O (1994). Formation of 8-hydroxy-2′-deoxyguanosine and 4-hydroxy-2-nonenal-modified proteins in human renal-cell carcinoma. Int J Cancer 1994; 58: 825-9.
74. Toyokuni S, Okamoto K, Yodoi J, Hiai H. Hypothesis: Persistent oxidative stress in cancer. FEBS Letters 1995; 358: 1-3.
75. Batist G, Tulpule A, Sinha BK, Katki AG, Meyers CE, Cowan KH. Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells. J Biol Chem 1986:261: 15544-9.
76. Nakagawa K, Saijo N, Tsuchida S, Sakai M, Tsunokawa Y, Yokata J, Muramatsu M, Terada M, Tew KD. Glutathione-S-transferase pi as a determinant of drug resistance in transfectant cell lines. J Biol Chem 1990; 265: 4296-301.
77. Fujii S, Nanbu Y, Nonogaki H, Konishi I, Mori T, Masutani H, Yodoi J. Coexpression of adult T-cell leukemia-derived factor, a human thioredoxin homologue, and human papillomavirus DNA in neoplastic cervecal squamous epithelium. Cancer 1991;68: 1583-91.
78. Nakamura H, Masutani H, Tagaya Y, Yamauchi A, Inamoto T, Nanbu Y, Fujii S, Ozawa K, Yodoi J. Expression and growth-promoting effect of adult T-cell leukemia- derived factor: a human thioredoxin homologue in hepatocellular carcinoma. Cancer 1992; 69: 2091-7.
79. Sakumi K, Furuichi M, Tsuzuki T, Kakuma T, Kawabata S, Maki H, Sekiguchi M. Cloning and expression of cDNA for a human enzyme that hydrolyzes 8-oxo-dGTP, a mutagenic substrate for DNA synthesis. J Biol Chem 1993; 268: 23524-30.
80. Okamoto K, Toyokuni S, Kim W-J, Ogawa O, Kakehi Y, Arao S, Hiai H, Yoshida O. Overexpression of human mutT homologue gene messenger RNA in renal cell carcnima: evidence of persistent oxidative stress in cancer. Int J Cancer 1996; 65: 437-41.